ESI-GROUP
20.10.2020 14:35:10 CEST | Business Wire | Press release
Launched in February 2020, the AMPLI project simulation, supported by the EIT Manufacturing and reuniting a consortium of five partners – ESI Group (Paris:ESI), coordinator of the project, Whirlpool, IPC (Innovation Plasturgie Composites), ENSAM and LMS (Laboratory for Manufacturing Systems & Automation) – will combine advantages of simulation and augmented reality to provide manufacturing workers with real-time knowledge and information. The project will bring an important step forward the digital transformation of European factories.
The plastics industry has already introduced enabling technologies to achieve zero-defect manufacturing and improve work cells flexibility such as in-mold sensors, in-line quality control, autonomous devices or predictive models. Augmented Reality (AR) offers new ways to interact not only with machines but also with manufacturing and product models. However, for further adoption, existing AR tools are still not specific enough to be relevant and need to offer dedicated platforms regarding each industrial domain.
The objective of the AMPLI project is to provide machine operators with real-time knowledge and information to improve decision-making and working procedures thanks to the development of an AR tool dedicated to the manufacturing value chain of polymer forming process. The AR tool will be based on the combination of plastic domain-based knowledge (from tuning, production and maintenance) and the integration of numerical simulation.
AMPLI project target 3 main benefits:
-
Improve manufacturing efficiency
- time reduction for tuning a work cell: -10%
- increase machinery availability by preventive maintenance: +8%
- reduction of training period of work force: -25%
- reduction of scraps: -10%
- Eliminate skill shortages by capturing and return process knowledge
- Increase attractivity of shop floor work by fostering the use of digital tools, which is appealing for young people. Work becomes more visual, accessibility increases and facilitates the training
AMPLI project approach is to embed and enable physically realistic virtual objects in a real environment to be interactive. It is based on the improvement of AR mechanisms and usability through:
- embedded process simulation results thanks to reduced order model
- customized plastic and composite processing interface by mixing measured information coming from the manufacturing work cell and information coming from models
The project is sponsored by the EIT Manufacturing (European Institute of Innovation & Technology) and is supported by a consortium of 5 European partners led by ESI Group. Together, and for a period of one year, the consortium partners will be working on developing, testing and validating AR and simulation technology dedicated to a thermoforming process.
ESI will be the integrator of the final output based on existing AR tool. This step will be particularly challenging and key as AR need real-time information to be efficient which will not be possible without ESI’s expertise and innovation technologies like its model-order reduction platform. IPC will provide knowledge rules regarding setting and supervision. They will use their skills in machine interoperability and process control as guidance for the project. Moreover, IPC simulates currently thermoforming process using ESI software PAM-FORM.
LMS has extensive experience in developing AR application for the manufacturing domain to support different steps of the lifecycle. Among other AR apps, LMS has developed an AR solution to support the maintenance phase of injection molds.
ENSAM will develop AR features to mix manufacturing process simulation with reality.
Whirlpool as plastic converter will provide requirements and a pilot case dedicated to thermoforming to test and validate the product at an industrial scale.
AMPLI will bring to the market a new product with AR integrating both plastic domain knowledge and simulation as differentiator.
In mid-term, such benefits will be transferred to other manufacturing processes.
Project title
: Augmented Mold for setting and supervision of PLastIc product manufacturing
Project Duration:
12 months
Project Consortium:
ENSAM, ESI Group, IPC, LMS, Whirlpool
About ESI
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.
Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
LinkedIn / Facebook / Twitter / Youtube
About the EIT & EIT Manufacturing
The European Institute of Technology and Innovation (EIT) is a body of the European Union and is an integral part of the Horizon 2020 program. EIT was established to support the innovators to change their best ideas to products, services and job positions for Europe. EIT consists of 8 Knowledge and Innovation Communities: EIT Manufacturing, EIT Climate-KIC, EIT Digital, EIT Food, EIT Health, EIT InnoEnergy, EIT RawMaterials, and EIT Urban Mobility.
EIT Manufacturing’s main goal is to bring European stakeholders focused on manufacturing together in innovation ecosystems that add unique value to European products, processes and services and inspire the creation of globally competitive and sustainable manufacturing. EIT Manufacturing associates more 50 organizations (universities, research institutes and business), such as Volkswagen, Volvo, Darmstadt University of Technology, the French Alternative Energies and Atomic Energy Commission (CEA), Siemens, Slovak University of Technology in Bratislava, Phillips, Procter & Gamble, and Whirlpool Europe to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005720/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
